SynthesisFrontiers in pharmacology2019
Incidence of Immune Checkpoint Inhibitor-Associated Diabetes: A Meta-Analysis of Randomized Controlled Studies.
Synthesis in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Islet function impairment outcomes of immune checkpoint inhibitors in cancer patients: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2020Pooled it
- Hyperglycemia during ICI Therapy: etiology, risk factors, and survival outcome.Journal of endocrinological investigation · 2026Article
- Impact of baseline nutritional and inflammatory markers on safety and efficacy of immune checkpoint inhibitors in cancer patients: a retrospective, monocentric study.Discover oncology · 2026Article
- Hyperglycemia in patients treated with immune checkpoint inhibitors: key clinical challenges and multidisciplinary consensus recommendations.Journal for immunotherapy of cancer · 2025Review
- Medication-Induced Hyperglycemia and Diabetes Mellitus: A Review of Current Literature and Practical Management Strategies.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Review
- Endocrine Adverse Events Related To Immune Checkpoint Inhibitor Treatment: Relationship Between Antibodies and Severity of Thyroid Dysfunction.Endocrine, metabolic & immune disorders drug targets · 2024Observational
- A Concerted Vision to Advance the Knowledge of Diabetes Mellitus Related to Immune Checkpoint Inhibitors.International journal of molecular sciences · 2023Review
- Risk of diabetes mellitus among users of immune checkpoint inhibitors: A population-based cohort study.Cancer medicine · 2023Article
- Immune cells and their inflammatory mediators modify β cells and cause checkpoint inhibitor-induced diabetes.JCI insight · 2022Article
- Adverse Events Associated with Immune Checkpoint Inhibitors: Overview of Systematic Reviews.Drugs · 2022Review
- When therapeutic drugs lead to diabetes.Diabetologia · 2022Review
- Immune Checkpoint Inhibitors and Risk of Type 1 Diabetes.Diabetes care · 2022Article
- Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literature.Reviews in endocrine & metabolic disorders · 2021Review
- Characterization of hyperglycemia in patients receiving immune checkpoint inhibitors: Beyond autoimmune insulin-dependent diabetes.Diabetes research and clinical practice · 2021Article
- Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review.Endocrine connections · 2020Review
- Response to Letter to the Editor: "Checkpoint Inhibitor-Associated Autoimmune Diabetes is Distinct From Type 1 Diabetes".The Journal of clinical endocrinology and metabolism · 2020Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.